Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of different treatments for Staphylococcus aureus bacteremia, a serious infection caused by the bacteria Staphylococcus aureus that enters the bloodstream. The trial will explore the impact of various antibiotics on the survival of patients over a period of 90 days. The antibiotics being studied include Rifampicin, Doxycycline, Co-trimoxazole, Cefazolin, Flucloxacillin, Daptomycin, Benzylpenicillin Sodium, Amoxicillin, Levofloxacin, Clindamycin, Cefalexin, Moxifloxacin, Linezolid, Clindamycin Hydrochloride, and Vancomycin. Some participants will receive a placebo for comparison.

The purpose of the study is to examine how these treatments affect the overall survival of patients with this infection. Participants will be monitored for 90 days to assess their health outcomes, including survival rates and any side effects from the treatments. The study will also look at how long patients stay in the hospital and their recovery progress.

Throughout the study, participants will receive either one of the antibiotics or a placebo, and their health will be closely observed. The trial aims to provide valuable information on the effectiveness of these antibiotics in treating Staphylococcus aureus bacteremia and improving patient outcomes. This research could help guide future treatment options for this serious infection.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Entry into the trial

    Upon joining the study, you will be informed about the trial's purpose, which is to examine the effect on all-cause mortality at 90 days of a range of interventions in patients with Staphylococcus aureus bacteremia.

    You will be asked to provide consent to participate in the trial, acknowledging that you understand the procedures and potential risks involved.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm that Staphylococcus aureus has been grown from at least one blood culture.

    You must be admitted to a participating hospital at the time of this assessment.

  3. Step 3

    Treatment allocation

    You will be randomly assigned to receive one of the following medications: rifampicin, doxycycline, co-trimoxazole, cefazolin, flucloxacillin, daptomycin, benzylpenicillin sodium, amoxicillin, levofloxacin, clindamycin, cefalexin, moxifloxacin, linezolid, clindamycin hydrochloride, or vancomycin.

    The route of administration will vary depending on the medication, including oral, intravenous, or IV infusion.

  4. Step 4

    Medication administration

    You will receive the assigned medication according to the specified dosage and frequency, which will be explained to you by the medical team.

    The duration of administration will be determined based on your response to the treatment and the study protocol.

  5. Step 5

    Monitoring and follow-up

    Throughout the trial, your health will be closely monitored to assess the effectiveness of the treatment and to identify any side effects.

    Follow-up assessments will occur at 14, 28, 42, and 90 days after entering the trial to evaluate your health status and any changes in your condition.

  6. Step 6

    Completion of the trial

    At the end of the 90-day period, a final assessment will be conducted to determine the overall outcome of the treatment.

    You will be informed about the results of the trial and any further steps that may be necessary for your health care.

Who can join the trial?

5 criteria

  • The patient must have a blood test that shows the presence of Staphylococcus aureus, a type of bacteria.
  • The patient must be admitted to a hospital that is participating in the study at the time they are being considered for the study. If the patient has passed away, they must have been admitted to the hospital from the time the blood test was taken until the time they were considered for the study.
  • The study is open to both male and female patients.
  • The study includes patients from certain age groups, specifically adults and older adults.
  • The study does not include vulnerable populations, which means it is not designed for groups that might need special protection or care.

Who cannot join the trial?

6 criteria

  • Patients with a different type of infection other than Staphylococcus aureus bacteremia cannot participate. Staphylococcus aureus bacteremia is a type of bacterial infection in the blood.
  • Patients who are under 18 years old or over 65 years old cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have a history of severe allergic reactions to the study medication cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients with a medical condition that the study doctors believe would make it unsafe for them to participate cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

{ "authorizedApplication.authorizedPartI.products.0": [ { "productName": "Vancomycin", "description": "Vancomycin is an antibiotic used to treat serious infections caused by bacteria. It works by stopping the growth of bacteria." }, { "productName": "Daptomycin", "description": "Daptomycin is an antibiotic that fights bacteria in the body. It is used to treat certain infections caused by bacteria." }, { "productName": "Linezolid", "description": "Linezolid is an antibiotic that is used to treat infections, including pneumonia and skin infections. It works by stopping the growth of bacteria." }, { "productName": "Ceftaroline", "description": "Ceftaroline is an antibiotic used to treat bacterial infections, including skin infections and pneumonia. It works by killing bacteria or preventing their growth." } ] } Vancomycin is an antibiotic used to treat serious infections caused by bacteria. It works by stopping the growth of bacteria. Daptomycin is an antibiotic that fights bacteria in the body. It is used to treat certain infections caused by bacteria. Linezolid is an antibiotic that is used to treat infections, including pneumonia and skin infections. It works by stopping the growth of bacteria. Ceftaroline is an antibiotic used to treat bacterial infections, including skin infections and pneumonia. It works by killing bacteria or preventing their growth.

What is already known about the treatment

Staphylococcus aureus Network Adaptive Platform trial (SNAP) – This clinical trial is focused on evaluating various treatments for Staphylococcus aureus bacteremia, a serious bloodstream infection. The main goal is to determine how these treatments affect the overall survival of patients 90 days after treatment. The trial is exploring different interventions to find the most effective way to reduce mortality in patients suffering from this condition. The study is ongoing, and its findings will contribute to medical literature by providing insights into the best therapeutic approaches for managing Staphylococcus aureus bacteremia.

Investigated diseases

Staphylococcus aureus bacteremia – Staphylococcus aureus bacteremia is a condition where the bacterium Staphylococcus aureus enters the bloodstream. This can lead to a systemic infection, affecting various organs and tissues. The disease often begins with symptoms such as fever, chills, and low blood pressure. As it progresses, it can cause complications like endocarditis, osteomyelitis, and abscess formation in different parts of the body. The bacteria can spread to the heart, bones, joints, and other areas, leading to more severe health issues. The progression of the disease depends on factors like the patient's immune system and the presence of any underlying health conditions.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-503582-35-00Estimated enrolment2 348 patientsSponsorUniversitair Medisch Centrum Utrecht

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.